ITUS Corporation (NYSE:ANIX)’s share price shot up 22.2% during trading on Thursday . The company traded as high as $2.98 and last traded at $2.97. 1,144,364 shares changed hands during trading, an increase of 359% from the average session volume of 249,427 shares. The stock had previously closed at $2.43.
Separately, Zacks Investment Research raised ITUS from a “sell” rating to a “hold” rating in a research note on Friday, September 25th.
The business’s 50 day simple moving average is $2.28 and its 200 day simple moving average is $2.28.
In related news, CEO Amit Kumar bought 28,000 shares of the stock in a transaction on Friday, September 11th. The stock was bought at an average price of $2.11 per share, with a total value of $59,080.00. Following the completion of the purchase, the chief executive officer now directly owns 262,000 shares in the company, valued at approximately $552,820. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Lewis H. Titterton, Jr. purchased 40,000 shares of the company’s stock in a transaction on Friday, September 11th. The shares were bought at an average price of $2.08 per share, with a total value of $83,200.00. Following the completion of the transaction, the director now owns 1,020,326 shares of the company’s stock, valued at $2,122,278.08. The disclosure for this purchase can be found here.
About ITUS (NYSE:ANIX)
Anixa Biosciences, Inc engages in the development, acquisition and licensing emerging technology in the field of biotechnology. It focuses on platform called Cchek, a series of inexpensive non-invasive blood tests for the early detection of cancer, which is based on the body’s immunological response to the presence of a malignancy.
Read More: What member countries make up the G-20?
Receive News & Ratings for ITUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ITUS and related companies with MarketBeat.com's FREE daily email newsletter.